Zymeworks (NASDAQ:ZYME) Issues Earnings Results

Zymeworks (NASDAQ:ZYME) released its quarterly earnings results on Monday. The company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.27 by $0.01, FiscalAI reports. The firm had revenue of $512.92 million for the quarter, compared to the consensus estimate of $227.40 million. Zymeworks had a return on equity of 25.07% and a net margin of 16.10%. The company’s revenue for the quarter was up 828.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.26) EPS.

Zymeworks Price Performance

Shares of NASDAQ:ZYME opened at $31.46 on Wednesday. The company’s 50-day moving average price is $27.50 and its two-hundred day moving average price is $25.42. Zymeworks has a one year low of $18.20 and a one year high of $31.97. The stock has a market capitalization of $2.22 billion, a PE ratio of 60.50 and a beta of 1.32.

Analysts Set New Price Targets

A number of research firms recently issued reports on ZYME. Citizens Jmp reiterated a “market outperform” rating and set a $32.00 price objective on shares of Zymeworks in a report on Wednesday, August 26th. Truist Financial boosted their target price on Zymeworks from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday. JPMorgan Chase & Co. boosted their target price on Zymeworks from $31.00 to $33.00 and gave the company an “overweight” rating in a research note on Thursday, September 3rd. Citigroup reaffirmed a “market outperform” rating on shares of Zymeworks in a research report on Monday, October 26th. Finally, B. Riley Financial reaffirmed a “buy” rating and set a $44.00 price target (up from $40.00) on shares of Zymeworks in a research note on Monday, August 10th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $42.25.

Key Headlines Impacting Zymeworks

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: Zymeworks raised its 2026 earnings guidance, a favorable signal for its outlook. Article: Zymeworks raises 2026 earnings guidance
• Positive Sentiment: Three firms raised their targets and maintained Buy ratings: TD Cowen to $39, Truist to $36, and HC Wainwright to $56. The revisions indicate continued analyst optimism, though targets are forecasts, not guarantees. TD Cowen recommendations
• Positive Sentiment: Third-quarter results showed a swing to profit, with EPS of $2.28 versus a loss a year earlier. One report put revenue at $256.5 million, above the $227.4 million FactSet estimate; another report gave a substantially different revenue figure, so the published totals are inconsistent. Article: Zymeworks Q3 2026 results
• Neutral Sentiment: The company’s profit was linked to a $250 million milestone payment from Jazz Pharmaceuticals. That payment boosted results, but investors may weigh how much earnings can be sustained without similar milestone revenue. Article: Zymeworks swings to a profit on a Jazz milestone
• Neutral Sentiment: A Zacks report said EPS of $2.28 missed its $2.40 estimate, although another cited consensus was $2.27, which the company narrowly beat. The differing benchmarks make the earnings comparison mixed. Article: Zymeworks misses Q3 earnings estimates
• Neutral Sentiment: A report listed short interest at zero shares as of November 10, implying no reported short position in that data; despite the article’s description of an increase, the figures show no days to cover.

Insider Activity at Zymeworks

In other news, EVP Adam Schayowitz sold 13,832 shares of the firm’s stock in a transaction dated Friday, October 9th. The stock was sold at an average price of $25.85, for a total value of $357,557.20. Following the completion of the transaction, the executive vice president owned 23,205 shares in the company, valued at $599,849.25. This trade represents a 37.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 37.73% of the stock is currently owned by corporate insiders.

About Zymeworks

Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.